{"id":456,"date":"2026-08-10T06:43:42","date_gmt":"2026-08-10T04:43:42","guid":{"rendered":"https:\/\/reborn-peptides.com\/knowledge\/understanding-the-coa\/"},"modified":"2026-09-04T12:17:58","modified_gmt":"2026-09-04T10:17:58","slug":"understanding-the-coa","status":"publish","type":"page","link":"https:\/\/reborn-peptides.com\/en\/knowledge\/understanding-the-coa\/","title":{"rendered":"What Is a Certificate of Analysis? Reading a Peptide COA"},"content":{"rendered":"

What is a certificate of analysis?<\/strong> A Certificate of Analysis, or COA, is an analytical document for one specific batch, not a quality seal. Its value comes from a traceable connection to the material, a named method and a result that can be reviewed. In the research-use setting, it helps laboratories establish exactly what was examined and how the reported finding is framed.<\/p>\n

This page explains how to read a peptide COA. It states no purity value or testing claim for specific material; the document assigned to the batch is decisive. Product pages such as BPC-157<\/a> and retatrutide<\/a> state no general purity value and refer the specific figure to the COA for the batch concerned.<\/p>\n

What a certificate of analysis is<\/h2>\n

A COA records selected analytical work on an identified sample. Its audience includes anyone reviewing research material who needs to connect a result to the physical item. It answers limited questions: which sample was represented, which method was named, what result was reported and who or what process released the document.<\/p>\n

That function separates an analytical record from marketing language. A general supplier statement cannot show that a particular result belongs to the item at hand. The batch reference is therefore not a minor administrative detail: it is the link that makes every other field relevant to the received material.<\/p>\n

The fields a peptide COA carries<\/h2>\n

Substance and sample designation<\/h3>\n

The designation records what was analysed. Names and forms should agree with the sample description and label; wording alone does not establish identity.<\/p>\n

Batch or lot number<\/h3>\n

The lot number links the record to labelled material. It should match the product identification; a printed number has no value if identifiers disagree.<\/p>\n

Manufacturing and analysis dates<\/h3>\n

Dates place manufacture and analysis in time and distinguish records. They provide neither stability evidence nor a connection to a later batch.<\/p>\n

Method used<\/h3>\n

The method field names the analytical route for a result. It defines scope but does not demonstrate methodological quality.<\/p>\n

Result and result type<\/h3>\n

The result reports a test output; its type states whether that output represents peak area, content, identity support or another measured parameter.<\/p>\n

Testing body or responsible person<\/h3>\n

An identified testing body or responsible role supports attribution and discrepancy review. A name or signature alone proves neither independence nor analytical quality.<\/p>\n

Release status and document version<\/h3>\n

Sign-off, release wording and version identify the reviewed record and revisions. They cannot broaden tests or repair another mismatch.<\/p>\n

HPLC purity \u2014 what the chromatogram actually measures<\/h2>\n

HPLC separates components as they travel through a chromatographic column. Detector responses appear as peaks, and integrated peak area expresses each detected peak as a share of the included signal. Area percentage therefore describes relative composition among material detected under stated conditions, not absolute content of the sample. Interpretation depends on the method: the column, mobile phase, detector and integration rules affect what appears and is counted. Components that do not respond, co-elute or fall below detection or quantitation limits may not be represented reliably. A peptide COA should therefore connect the value to the HPLC method and result type. The chromatogram supports review, but its percentage cannot be read apart from that scope.<\/p>\n

As a methodological example, Esposito S et al. (2012) used HPLC coupled with high-resolution mass spectrometry to identify an N-terminally acetylated peptide fragment in an examined product; a detection procedure for biological samples was only proposed, not validated (PMID 22962027<\/a>; DOI 10.1002\/dta.1402<\/a>).<\/p>\n

What mass spectrometry adds<\/h2>\n

Mass spectrometry compares a measured mass-related signal with the calculated mass expected for the stated molecule. Agreement can support an identity assignment when the method, ion forms and interpretation are appropriately documented. It does not by itself determine how much target material is present. Nor does a matching mass establish chromatographic purity: other components may be present, and species with similar or overlapping signals require suitable resolution and interpretation. On a peptide COA, an MS result should therefore be read as identity evidence within the stated method, not as a substitute for a content result or an HPLC area percentage.<\/p>\n

As a methodological example, Avliyakulov NK et al. (2026) used LC-HRMS to identify in vitro metabolites (PMID 41688415<\/a>; DOI 10.1002\/dta.70035<\/a>).<\/p>\n

Why the batch number carries the document<\/h2>\n

Review begins by comparing the lot number on the COA with the material label. If they differ, the result belongs to another documented batch and says nothing about the material under review. A similar name or earlier record cannot bridge that gap.<\/p>\n

The label and material must therefore remain connected throughout laboratory records. If either loses its identifier, the analytical document cannot restore the connection by assumption. The lyophilised material and vials overview<\/a> explains the supplied solid form, container and label context that sits beside this document review.<\/p>\n

What the reported result does and does not mean<\/h2>\n

A reported value is limited to its stated method and result type. On its own, it does not automatically describe absolute content, identity or components outside the measurement. The guide to purity, HPLC and MS<\/a> covers the methods in more depth; during document review, check that every output remains connected to its method and scope.<\/p>\n

Reading a result given as area percent<\/h2>\n

An area-percent result compares the integrated area of one chromatographic peak with the total peak area included in the calculation. The number may describe the target peak’s share of detected signals under the recorded conditions. It is not automatically a mass fraction, an assay of total peptide content or an account of everything in the sample. The reviewer should check how the peak was assigned, which peaks were included or excluded, and whether the chromatogram and method details support the calculation. Detection limits, co-elution and detector response remain relevant. The value should be reported as an HPLC area percentage when that is what the method produced.<\/p>\n

As a methodological example, M\u00f6ller J et al. (2026) used LC-HR-MS\/MS for in vitro metabolism analysis, with selected synthesised metabolites confirmed by NMR (PMID 41588687<\/a>; DOI 10.1002\/rcm.70039<\/a>).<\/p>\n

How to read a peptide COA in order<\/h2>\n

There is no single correct starting point, but there is a sequence that keeps the identifiers in front of the interpretation. The short answer to how to read a certificate of analysis is to settle the connection to the material first and the numbers second.<\/p>\n

    \n
  1. Match the batch or lot identifier on the document to the product label exactly.<\/li>\n
  2. Confirm that the substance and sample designation are unambiguous, including any stated form or modification.<\/li>\n
  3. Check that the manufacturing and analysis dates are visible and connected to the same record.<\/li>\n
  4. Identify the method named for each result and the testing body or responsible role shown on the document.<\/li>\n
  5. Determine whether each output is described as peak area, content, identity support or another result type.<\/li>\n
  6. Check whether an identity method is explicitly present when identity is being reported; do not infer it from another test.<\/li>\n
  7. Reconcile the release status, sign-off and document version so they plausibly refer to one current record.<\/li>\n<\/ol>\n

    Open points are recorded as questions for resolution, not filled with guesses. A complete-looking layout does not override a missing identifier, unclear result type or conflicting version.<\/p>\n

    What a peptide COA does not prove<\/h2>\n

    A COA does not prove efficacy or suitability for a purpose. It does not support conclusions about another batch, and it does not establish storage stability. Sterility or freedom from endotoxins is not established unless the relevant characteristic was examined with a suitable method and explicitly reported. The same limitation applies to content and identity: each requires its own suitable, stated method and result.<\/p>\n

    Storage stability is a separate evidence question covered in storage and handling<\/a>. Published research is also a different evidence stream: the study-models guide<\/a> explains how literature should be interpreted without treating it as a batch document. Neither storage records nor literature can substitute for the COA assigned to the material under review.<\/p>\n

    Independent verification and supplier documents<\/h2>\n

    A supplier statement remains a supplier statement; it is not independent verification. Peptide COA testing carried out in-house produces a document, not an independent confirmation, and the two are easily conflated. The description \u201cthird party tested peptides\u201d is supportable only when the testing body and the documentation genuinely establish that relationship. A reviewer should look for consistent sample and lot identifiers, attributable testing information, a clear method-to-result connection, and a coherent release status rather than relying on the phrase itself.<\/p>\n

    Reborn’s governing principle is that purity statements remain batch-specific and accompanied by the corresponding document, while supplier statements do not replace independent verification. Product documentation follows the same rule: pages such as BPC-157<\/a> and retatrutide<\/a> state no general purity value and refer the specific figure to the COA for the batch concerned.<\/p>\n

    That governing principle is a documentation standard, not a claim that a particular Reborn batch has already followed a confirmed testing route or that its document is publicly linkable.<\/p>\n

    Frequently asked questions about a peptide COA<\/h2>\n

    Are purity and identity the same finding?<\/h3>\n

    No. Chromatographic area percentage describes peak areas under stated conditions, while a suitable identity method supports assignment of the molecule. Each finding needs its own method, result and scope.<\/p>\n

    What does the batch number establish?<\/h3>\n

    It connects the document to labelled material when the identifiers match exactly. It does not validate the analysis itself, but without that match the reported result cannot be assigned to the material under review.<\/p>\n

    Does a COA prove safety or suitability?<\/h3>\n

    No. A COA reports only the characteristics actually examined with the stated methods. It does not establish safety, efficacy, suitability for a purpose, stability, sterility or endotoxin status unless the relevant test is explicitly reported.<\/p>\n

    What makes a document difficult to verify?<\/h3>\n

    Warning signs include a missing or mismatched lot identifier, an unnamed testing body, no method-to-result connection, unclear result types, absent sign-off or conflicting versions. Such gaps should be recorded and resolved, not filled by assumption.<\/p>\n

    Sources<\/h2>\n

    The sources below serve exclusively as methodological examples of analytical techniques. They do not document Reborn material or any specific Reborn batch.<\/p>\n

      \n
    1. Esposito S et al. (2012), Drug Testing and Analysis<\/em> 4(9):733-8. PMID 22962027<\/a>. DOI: 10.1002\/dta.1402<\/code><\/a>. In vitro \/ analytical model (HPLC with high-resolution mass spectrometry).<\/li>\n
    2. Avliyakulov NK et al. (2026), Drug Testing and Analysis<\/em> 18(3):439-450. PMID 41688415<\/a>. DOI: 10.1002\/dta.70035<\/code><\/a>. In vitro \/ analytical model (LC-HRMS).<\/li>\n
    3. M\u00f6ller J et al. (2026), Rapid Communications in Mass Spectrometry<\/em> 40(8):e70039. PMID 41588687<\/a>. DOI: 10.1002\/rcm.70039<\/code><\/a>. In vitro \/ analytical model (LC-HR-MS\/MS with NMR confirmation).<\/li>\n<\/ol>\n

      Research-use statement<\/h2>\n

      All materials referenced on this page are for laboratory research use only and are not for human or veterinary use. This guide explains document review and does not replace the analytical record, label, acceptance criteria or controlled procedures applicable to the specific batch.<\/p>\n","protected":false},"excerpt":{"rendered":"

      What is a certificate of analysis? A Certificate of Analysis, or COA, is an analytical document for one specific batch, not a quality seal. Its value comes from a traceable connection to the material, a named method and a result that can be reviewed. In the research-use setting, it helps laboratories establish exactly what was […]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":445,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-456","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages\/456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/comments?post=456"}],"version-history":[{"count":0,"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages\/456\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/pages\/445"}],"wp:attachment":[{"href":"https:\/\/reborn-peptides.com\/en\/wp-json\/wp\/v2\/media?parent=456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}